Redox-responsive ferrocene-containing poly(ionic liquid)s for antibacterial applications
- 26 Downloads
Ferrocene (Fc)-containing imidazolium type ionic liquids (ILs) and corresponding poly(ionic liquid) (PIL) membranes with tunable antibacterial activity based on electrochemical redox reaction and host-guest chemistry were developed. The effect of Fc moiety on the antimicrobial activities against both Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) was studied by minimum inhibitory concentration (MIC). The presence of Fc groups highly enhanced the antibacterial efficiency of Fccontaining ILs because of the generation of reactive oxygen species (ROS). The electrochemical oxidation of Fc to Fc+ and the formation of inclusion complexes between Fc and β-CD via host-guest interactions decreased the antibacterial activities of ILs and PIL membranes. The antibacterial activities may be recovered in some extent upon the electrochemical reduction of Fc+ to Fc or the exclusion of the Fc out of the cavity of β-CD. Furthermore, all the Fc-containing PIL membranes showed relatively low hemolysis activities and none cytotoxicity toward human cells, indicating clinical feasibility in topical applications.
Keywordsantibacterial activities imidazolium cations ferrocene poly(ionic liquid) cytotoxicity
Unable to display preview. Download preview PDF.
This work was supported by the National Science Foundation for Distinguished Young Scholars (21425417), the National Natural Science Foundation of China (21704071), the Jiangsu Province Science Foundation for Youth (BK20170332), General Program Foundation of Jiangsu Province University Science Research Project (17KJB150033), General Program Foundation of Shanghai Municipal Commission of Health and Family Planning (201740107), and the Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions, and Science and Technology Innovation Fund Project of Zhongshan Hospital, Fudan University (2017ZSCX03).
- 33.Savjani KT, Gajjar AK, Savjani JK. ISRN Pharm, 2012, 2012: 1–10Google Scholar
- 34.Chaudhary VB, Patel JK. Int J Pharm Sci Res, 2013, 4: 68–76Google Scholar
- 45.Beveridge TJ. J Bacteriol, 1999, 181: 4725–4733Google Scholar
- 47.Acevedo-Morantes CY, Melendez E, Singh SP, Ramirez-Vick JE. J Cancer Sci Ther, 2012, 4: 271–275Google Scholar